WithdrawnPhase 2NCT03982537
Effect of N-Acetyl Cysteine (NAC) on the Oral Microbiome
Studying Squamous cell carcinoma of the oral cavity
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Wake Forest University Health Sciences
- Principal Investigator
- Mercedes Porosnicu, MD, MDWake Forest University Health Sciences
- Intervention
- N-Acetyl-L-Cysteine dietary supplement(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2020
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03982537 on ClinicalTrials.govOther trials for Squamous cell carcinoma of the oral cavity
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07371611Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell CarcinomaQunxing Li,MD
- RECRUITINGPHASE1NCT06736379Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck CancerVLP Therapeutics
- RECRUITINGPHASE2NCT06627270Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral CancerCase Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06353685De-Escalation Postoperative Radiotherapy for Oral Squamous Cell Carcinoma With pCR/MPR.Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- RECRUITINGPHASE3NCT06258811Neoadjuvant Immunochemotherapy for LAOSCCLai-ping Zhong
- RECRUITINGPHASE2, PHASE3NCT06030440De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and NeckUniversity of Erlangen-Nürnberg Medical School
- RECRUITINGNANCT05793151Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant TherapyMedical University of South Carolina
- RECRUITINGPHASE2NCT06130332Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See all trials for Squamous cell carcinoma of the oral cavity →